Delivering the best care to the right patient at the right time

June 25, 2013

There are two popular models when it comes to delivering the best healthcare – using evidence-based guidelines or applying personalized medicine. Each method has its own merits and drawbacks, but according to one Northwestern Medicine cardiologist, when the two theories are integrated the result is an optimal healthcare delivery model that is both less expensive and better for the patient.

"It should not be one or the other but instead a combination of both," said Jeffrey Goldberger, MD, an attending and cardiac electrophysiologist at Northwestern Memorial Hospital and director of Cardiac Electrophysiology Research at Northwestern's Bluhm Cardiovascular Institute.

"My interest in evidence-based medicine and personalized medicine stems from my involvement in the problem the medical community has in identifying patients who are at risk for sudden cardiac deaths. Using the guidelines I outlined in my article, I think we can better treat patients with implantable defibrillators. Based on the research, we are clearly over treating some patients and not treating other patients who would benefit."

Goldberger's research was published in a June 25, 2013 article in The Journal of the American Medical Association (JAMA). Evidence-based medicine dates back to but gained popularity in the 1990s. It consists of basing treatment on the body of clinical data and clinical trials available. Personalized medicine is tailoring medical treatment to the individual characteristics of each patient, focusing on a patient's family history, , or other characteristics.

According to Goldberger, who is also a professor at Northwestern University Feinberg School of Medicine, physicians should not follow one theory over the other. Instead, they should bring in personalized medicine to treat those subgroups not helped using evidence-based guidelines, he said.

"For example, many physicians administer a thrombolytic, or clot-dissolving drug, when someone is having a heart attack because the clinical data show those drugs help most patients," Goldberger said. "However, for some older patients these drugs can cause a stroke, so it's best to use to determine the best treatment for these older patients."

"Cultivating a healthcare culture poised to explore these opportunities is critical, but it will entail active participation from a whole range of stakeholders, including physicians, insurers, regulators and healthcare organizations," Goldberger added. "By combining both theories, we have a real opportunity to deliver more precise treatments to the exact patient population who needs it."

In addition to his clinical practice and teaching, Goldberger is an editorial consultant and reviewer for more than 20 medical journals. His clinical interests include pacemakers, cardiac rhythm disorders, catheter ablation, implantable defibrillators and supraventricular tachycardia.

Explore further: Elderly benefit from using implantable defibrillators

More information: jama.jamanetwork.com/article.a … px?articleid=1691756

Related Stories

Elderly benefit from using implantable defibrillators

June 17, 2013
The elderly may benefit from implantable cardioverter defibrillators as much as younger people, according to new research in the American Heart Association journal Circulation.

Practical approach makes new ESC cardiac pacing and resynchronization guidelines accessible to all

June 25, 2013
The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy¹ developed in collaboration with the European Heart Rhythm Association (EHRA), have created a new classification system for bradyarrhythmias ...

ACC/HRS release appropriate use criteria for ICDs and CRT

February 28, 2013
The American College of Cardiology and the Heart Rhythm Society, along with key specialty societies, today released appropriate use criteria for implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization ...

Cancer biorepository speeds clinical trials, drug development, analysis shows

May 8, 2013
Researchers at Moffitt Cancer Center say identifying and selecting participants for phase II cancer clinical trials from a centralized warehouse of patient-donated biological data expedites participant accrual, reduces trial ...

Potentially life-saving cooling treatment rarely used for in-hospital cardiac arrests

June 21, 2013
The brain-preserving cooling treatment known as therapeutic hypothermia is rarely being used in patients who suffer cardiac arrest while in the hospital, despite its proven potential to improve survival and neurological function, ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.